EBS News and Press, Emergent Biosolutions Inc. From 03/17/23

2023-03-17 08:33:13 ET Diebold Nixdorf DBD -28% on liquidity concerns . Sarepta Therapeutics SRPT -18% on FDA advisory meeting for its muscular dystrophy treatment . ThermoGenesis ( THMO ) -19% . First Republic Bank FRC -15% after suspending d...

2023-03-09 08:10:06 ET Shares of Emergent BioSolutions ( NYSE: EBS ) are up 5% in premarket trading after a number of institutional investors and hedge funds increased their holdings. Eagle Asset Management Inc. owns 160,153 shares with a value of $3.361M following a p...

Emergent BioSolutions (NYSE: EBS) probably wishes it had stayed in bed on Tuesday. The company's stock declined by nearly 12% that day, following its release of quarterly results that fell well short of expectations on the bottom line. For its fourth quarter of 2022, Emergent booked rev...

Gainers: Cardio Diagnostics ( CDIO ) +159% . Bioventus ( BVS ) +68% . CNS Pharmaceuticals ( CNSP ) +24% . Bullfrog AI ( BFRG ) +20% . SI-BONE ( SIBN ) +19% . Losers: ContraFect ( CFRX ) -24% . AdaptHealth ( AHCO ) ...

The following slide deck was published by Emergent BioSolutions Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Emergent BioSolutions Inc. 2022 Q4 - Results - Earnings Call Presentation

Emergent BioSolutions Inc. (EBS) Q4 2022 Earnings Conference Call February 27, 2023, 5:00 PM ET Company Participants Bob Burrows - Vice President, Investor Relations Bob Kramer - President and CEO Rich Lindahl - Chief Financial Officer Conference Call Participant...

Image source: The Motley Fool. Emergent BioSolutions (NYSE: EBS) Q4 2022 Earnings Call Feb 27, 2023 , 5:00 p.m. ET Operator Continue reading For further details see: Emergent BioSolutions (EBS) Q4 2022 Earnings Call Transcript

Emergent Biosolutions press release ( NYSE: EBS ): Q4 Non-GAAP EPS of -$0.31 misses by $0.25 . Revenue of $330.7M (-54.3% Y/Y) beats by $32.47M . Sees FY 2023 revenue of $1.10B to $1.20B. The consensus FY 2023 revenue estimate is $1.17B. Sees Q1 2023 revenue of...

Reports Q4 2022 total revenues of $331M resulting in FY 2022 total revenues of $1,121M, in line with prior guidance Reports Q4 2022 net loss of $88M and FY 2022 net loss of $224M Reports Q4 2022 adjusted EBITDA of $34M and FY 2022 adjusted EBITDA of $26M, in line with prior guidance R...

Emergent Biosolutions ( NYSE: EBS ) is scheduled to announce Q4 earnings results on Monday, February 27th, after market close. The consensus EPS Estimate is $0.07 (compared to $4.5 in year ago quarter) and the consensus Revenue Estimate is $291.27M (-59.7% Y/Y). Over the last ...